Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Agarwal Website

Piyush K. Agarwal, M.D.

Selected Publications

1)  Johar RS, Hayn MH, Stegemann AP, Ahmed K, Agarwal P, Balbay MD, Hemal A, Kibel AS, Muhletaler F, Nepple K, Pattaras JG, Peabody JO, Palou Redorta J, Rha K, Richstone L, Saar M, Schanne F, Scherr DS, Siemer S, Stökle M, Weizer A, Wiklund P, Wilson T, Woods M, Yuh B, Guru KA.
Complications After Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
Eur. Urol. [Epub ahead of print], 2013.
[Journal]
2)  Marshall SJ, Hayn MH, Stegemann AP, Agarwal PK, Badani KK, Balbay MD, Dasgupta P, Hemal AK, Hollenbeck BK, Kibel AS, Menon M, Mottrie A, Nepple K, Pattaras JG, Peabody JO, Poulakis V, Pruthi RS, Palou Redorta J, Rha K, Richstone L, Schanne F, Scherr DS, Siemer S, Stöckle M, Wallen EM, Weizer AZ, Wiklund P, Wilson T, Woods M, Guru KA.
Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC).
BJU Int. [Epub ahead of print], 2013.
[Journal]
3)  Vourganti S, Harbin A, Singer EA, Shuch B, Metwalli AR, Agarwal PK.
Low Grade Micropapillary Urothelial Carcinoma, Does It Exist? - Analysis of Management and Outcomes from the Surveillance, Epidemiology and End Results (SEER) Database.
J Cancer. 4: 336-42, 2013.
[Journal]
4)  Guru KA, Peabody JO, Ahmed K, Kibel A, Weizer A, Hayn M, Johar R, Agarwal P, Balbay M, Hemal A, Muhletaler F, Nepple K, Pattaras J, Redorta J, Rha K, Richstone L, Saar M, Schanne F, Scherr D, Siemer S, Stoekle M, Wilson T, Woods M, Yuh B, Wiklund P.
Reply from Authors re: Manfred P. Wirth, Johannes Huber. What Really Matters Is Rarely Measured: Outcome of Routine Care and Patient-reported Outcomes. Robot-assisted Versus Open Radical Cystectomy: Beating a Dead Horse.
Eur. Urol. [Epub ahead of print], 2013.
[Journal]
5)  Li QQ, Wang G, Liang H, Li JM, Huang F, Agarwal PK, Zhong Y, Reed E.
ß-Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas.
Anticancer Res. 33: 1421-8, 2013.
[Journal]
6)  Trinh Q, Sun M, Kim SP, Sammon J, Kowalczyk KJ, Friedman AA, Sukumar S, Ravi P, Muhletaler F, Agarwal PK, Shariat SF, Hu JC, Menon M, Karakiewicz PI.
The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy.
Urol. Oncol. [Epub ahead of print], 2013.
[Journal]
7)  Trinh Q, Sun M, Sammon J, Bianchi M, Sukumar S, Ghani KR, Jeong W, Dabaja A, Shariat SF, Perrotte P, Agarwal PK, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.
Disparities in access to care at high-volume institutions for uro-oncologic procedures.
Cancer. [Epub ahead of print], 2012.
[Journal]
8)  Kheterpal E, Sammon JD, Diaz M, Bhandari A, Trinh Q, Pokala N, Sharma P, Menon M, Agarwal PK.
Effect of metabolic syndrome on pathologic features of prostate cancer.
Urol. Oncol. [Epub ahead of print], 2012.
[Journal]
9)  Trinh Q, Sun M, Sammon J, Tian Z, Bianchi M, Shariat SF, Jeong W, Ghani KR, Jeldres C, Perrotte P, Agarwal PK, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.
Leapfrog volume thresholds and perioperative complications after radical prostatectomy.
Cancer. [Epub ahead of print], 2012.
[Journal]
10)  Agarwal PK.
Editorial comment.
J. Urol. 185: 1261, 2011.
[Journal]
11)  Fujisue Y, Azuma H, Inamoto T, Komura K, Agarwal PK, Masuda H, Watsuji T, Katsuoaka Y.
Neoadjuvant hormonal therapy does not impact the treatment success of high-intensity focused ultrasound for the treatment of localized prostate cancer.
World J Urol. 29: 689-94, 2011.
[Journal]
12)  Agarwal PK, Sammon J, Bhandari A, Dabaja A, Diaz M, Dusik-Fenton S, Satyanarayana R, Simone A, Trinh QD, Baize B, Menon M.
Safety profile of robot-assisted radical prostatectomy: a standardized report of complications in 3317 patients.
Eur. Urol. 59: 684-98, 2011.
[Journal]
13)  Black PC, Shetty A, Brown GA, Esparza-Coss E, Metwalli AR, Agarwal PK, McConkey DJ, Hazle JD, Dinney CP.
Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis.
BJU Int. 106: 1799-804, 2010.
[Journal]
14)  Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke A, Pisters LL, Swanson DA, Dinney CP, Kamat AM.
Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy.
Urology. 73: 147-52, 2009.
[Journal]
15)  Agarwal PK, Black PC, Kamat AM.
Considerations on the use of diagnostic markers in management of patients with bladder cancer.
World J Urol. 26: 39-44, 2008.
[Journal]
16)  Kassouf W, Agarwal PK, Herr HW, Munsell MF, Spiess PE, Brown GA, Pisters L, Grossman HB, Dinney CP, Kamat AM.
Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC.
J. Clin. Oncol. 26: 121-6, 2008.
[Journal]
17)  Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR.
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes.
Cancer. 112: 307-14, 2008.
[Journal]
18)  Agarwal PK, Black PC, McConkey DJ, Dinney CP.
Emerging drugs for targeted therapy of bladder cancer.
Expert Opin Emerg Drugs. 12: 435-48, 2007.
[Journal]
19)  Black PC, Agarwal PK, Dinney CP.
Targeted therapies in bladder cancer--an update.
Urol. Oncol. 25: 433-8, 2007.
[Journal]
20)  Agarwal PK, Oefelein MG.
Testosterone replacement therapy after primary treatment for prostate cancer.
J. Urol. 173: 533-6, 2005.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 9/15/2013.